# DEBIRI Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases

> **NCT06177288** · NA · UNKNOWN · sponsor: **Fudan University** · enrollment: 39 (estimated)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **COMBINATION_PRODUCT:** DEBIRI Combined With Chemotherapy and Bevacizumab

## Key facts

- **NCT ID:** NCT06177288
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2023-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06177288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06177288, "DEBIRI Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06177288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*